MX2023009950A - Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta. - Google Patents

Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta.

Info

Publication number
MX2023009950A
MX2023009950A MX2023009950A MX2023009950A MX2023009950A MX 2023009950 A MX2023009950 A MX 2023009950A MX 2023009950 A MX2023009950 A MX 2023009950A MX 2023009950 A MX2023009950 A MX 2023009950A MX 2023009950 A MX2023009950 A MX 2023009950A
Authority
MX
Mexico
Prior art keywords
antibodies
delta
gamma
bind
cell receptors
Prior art date
Application number
MX2023009950A
Other languages
English (en)
Spanish (es)
Inventor
Hulsik David Lutje
Der Vliet Johannes Jelle Van
Robertus Cornelis Roovers
Paul Willem Henri Ida Parren
Jurjen Matthijs Ruben
Charlotte Merette Mousset
Original Assignee
Lava Therapeutics N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lava Therapeutics N V filed Critical Lava Therapeutics N V
Publication of MX2023009950A publication Critical patent/MX2023009950A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2023009950A 2021-02-26 2022-02-28 Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta. MX2023009950A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21159698 2021-02-26
US202163166339P 2021-03-26 2021-03-26
US202163274709P 2021-11-02 2021-11-02
EP21211114 2021-11-29
PCT/EP2022/054993 WO2022180271A1 (en) 2021-02-26 2022-02-28 Antibodies that bind CD123 and gamma-delta T cell receptors

Publications (1)

Publication Number Publication Date
MX2023009950A true MX2023009950A (es) 2023-11-10

Family

ID=80786427

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009950A MX2023009950A (es) 2021-02-26 2022-02-28 Anticuerpos que se unen a cd123 y receptores de linfocitos t gamma-delta.

Country Status (9)

Country Link
US (1) US20240141071A1 (cg-RX-API-DMAC10.html)
EP (1) EP4298125A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024507937A (cg-RX-API-DMAC10.html)
KR (1) KR20230169950A (cg-RX-API-DMAC10.html)
AU (1) AU2022225091A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017099A2 (cg-RX-API-DMAC10.html)
CA (1) CA3209454A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023009950A (cg-RX-API-DMAC10.html)
WO (1) WO2022180271A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4292610A1 (en) * 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Variant antibodies that bind gamma-delta t cell receptors
WO2025012118A2 (en) * 2023-07-07 2025-01-16 LAVA Therapeutics N.V. 5t4 binding agents and methods of use
CN118496370A (zh) * 2024-06-07 2024-08-16 南方医科大学深圳医院 一种靶向alox5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
FR2879605B1 (fr) 2004-12-16 2008-10-17 Centre Nat Rech Scient Cnrse Production de formats d'anticorps et applications immunologiques de ces formats
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 1가 항체 및 그의 제조 방법
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
AU2010229705A1 (en) 2009-03-27 2011-10-20 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
WO2012023053A2 (en) 2010-08-16 2012-02-23 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
WO2013157953A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
DK2924052T3 (da) 2012-11-21 2019-09-30 Pharmabcine Inc Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme
US10501540B2 (en) 2014-04-10 2019-12-10 Lava Therapeutics B.V. Immunoglobulins binding human Vγ9 Vδ2 T cell receptors
TW202010757A (zh) * 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
JP7457007B2 (ja) * 2018-09-19 2024-03-27 ラヴァ・セラピューティクス・エヌ・ヴイ 二重作用CD1d免疫グロブリン
CN114040926B (zh) * 2019-05-04 2025-07-29 印希比生物科学有限公司 结合cd123的多肽及其用途
JP7686571B2 (ja) 2019-05-08 2025-06-02 ヤンセン バイオテツク,インコーポレーテツド T細胞媒介性免疫を調節するための材料及び方法

Also Published As

Publication number Publication date
US20240141071A1 (en) 2024-05-02
CA3209454A1 (en) 2022-09-01
KR20230169950A (ko) 2023-12-18
JP2024507937A (ja) 2024-02-21
WO2022180271A1 (en) 2022-09-01
AU2022225091A1 (en) 2023-09-07
BR112023017099A2 (pt) 2023-11-21
EP4298125A1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
MX2023000448A (es) Anticuerpos que se unen a antígeno de membrana específico de la próstata (psma) y receptores de celulas t gamma-delta.
MX2023006832A (es) Anticuerpos que se unen a receptores de linfocitos t gamma-delta.
MX2024015502A (es) Anticuerpos variantes que se unen a los receptores de linfocitos t gamma-delta
ZA202308021B (en) Anti-ctla4 antibodies and methods of making and using the same
ZA202102223B (en) Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2022004430A (es) Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3).
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
MY203138A (en) Anti-il2 receptor gamma antigen-binding proteins
ZA202006481B (en) Anti-msr1 antibodies and methods of use thereof
NZ756763A (en) Engineered transferrin receptor binding polypeptides
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
MY155603A (en) Notch-binding agents and antagonists and methods of use thereof
UA130540C2 (uk) Композиція антитіла b7-h4
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
MX2024011444A (es) Anticuerpos anti-npr1 y usos de los mismos.
MX2021005085A (es) Formulacion de anticuerpo.
PH12022551166A1 (en) Compositions and methods for activation of integrins
MX2024012567A (es) Composiciones farmaceuticas de anticuerpos biespecificos anti-cd20/anti-cd3 y metodos de uso
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
MY170404A (en) Antigen binding proteins
MX2023005346A (es) Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8.
WO2022032005A3 (en) Il10rb binding molecules and methods of use
MX2024007091A (es) Anticuerpos caninizados y felinizados contra el ngf humano.